Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Santarus, Inc. (SNTS): Passive Hedge Fund Just Upped Its Stake By 149%

A market-moving update, Jacob Gottlieb’s Visium Asset Management purchased 2,294,704 shares of Santarus, Inc. (NASDAQ:SNTS) in a 13G filing with the Securities and Exchange Commission. Altogether, the position in Santarus, Inc.  is now valued at around 3,834,704, an increase of 149%.

Santarus, Inc. (NASDAQ:SNTS)

Looking at the entire picture, 13Gs indicate the intentions of passive hedge fund managers. These members of the smart money aren’t exposed to an equal level of popularity as their activist peers, but passive managers must be watched in a similar light.

To put it simply, it’s very beneficial for average investors to pay attention to Jacob Gottlieb’s latest investment into Santarus, Inc. (NASDAQ:SNTS).

Though It’s important to pay attention to many equity-based metrics, there’s one that is often overlooked: aggregate hedge fund sentiment.

Empirical studies have demonstrated that retail investors who follow specific hedge fund activity can outperform the S&P 500 by an average of 18 percentage points per year (see the details here).

Focusing in onSantarus, Inc. (NASDAQ:SNTS), our records indicate that 18 other hedge funds were long Santarus, Inc. (NASDAQ:SNTS) at the end of last quarter. In particular, Kevin Kotler’s Broadfin Capital, Steven Cohen’s SAC Capital Advisors, and Mark Kingdon’s Kingdon Capital, held shares of Santarus, Inc., which is some of the best company anyone can be in the same vicinity as.

Moreover, we should mention some other positions in Visium Asset Management’s equity portfolio, aside from Santarus, Inc..

As follows, they include MannKind Corporation (NASDAQ:MNKD), PDL BioPharma Inc. (NASDAQ:PDLI) and PDL BioPharma Inc. (NASDAQ:PDLI), and are listed below:

Company Name # of Hedge Funds # of Insiders Buying # of Insiders Selling
MannKind Corporation (NASDAQ:MNKD) 8 2 0
PDL BioPharma Inc. (NASDAQ:PDLI) 14 0 0
Sarepta Therapeutics Inc (NASDAQ:SRPT) 16 0 1

With that being said, we’ll keep you updated about the smart money’s investment plays surrounding
Santarus, Inc. (NASDAQ:SNTS).

Click here to learn why you should track hedge funds

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!